HIV Treatment Bulletin - October 2003
HIVandHepatitis.com

The aim of this cross-sectional analytical study was to describe the alterations in the bone metabolism of HIV-seropositive patients and evaluate the effects of antiretroviral therapies. Published in the September 5, 2003 issue of AIDS, this cross-sectional analytical study was undertaken by researchers at the Medical Science School of the National University of Cordoba and Rawson Hospital, Cordoba, Argentina.

A total of 142 subjects (113 male, 29 female), aged 20-45 years were divided into four groups: group A, 33 HIV-seropositive antiretroviral-naïve patients; group B1, 36 HIV-seropositive patients on antiviral therapy for over one year, without protease inhibitors (PI); group B2, 42 HIV-seropositive patients on combined therapy containing PI for over one year; and group C, 15 healthy, HIV-seronegative subjects.

Bone mineral density (BMD) was determined by dual energy X-ray absorptiometry in total body, lumbar spine and proximal femur; and evaluation of serum osteocalcin, d-pyridinoline, parathyroid hormone (THP), calcium and phosphate, and urine calcium.

BMD was significantly lower in HIV-seropositive patients in comparison with healthy controls, in all sites studied. However, no statistical differences were observed among all groups of HIV-infected patients, independently of the antiretroviral therapy.

There was a significantly higher occurrence of osteopaenia and osteoporosis in HIV-infected patients in comparison with controls (P < 0.0001), with no differences among treatment-naïve patients and either of the treatment groups. Bone formation and resorption markers were similar among all studied groups. There was a significant correlation in all bone sites between time of infection and BMD (P < 0.02).

BMD was significantly lower in HIV-seropositive patients in comparison with controls in lumbar spine, proximal femur and total body, without significant differences among treatment-naïve patients and either of the treatment groups.

Only time with HIV infection and not specific therapy was associated with BMD decreases.

Source: HIVandHepatitis.com

Ref: Bruera D et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003 Sep 5;17(13):1917-23.

© Copyright 2002 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted (email publisher@HIVandHepatitis.com).

031010
IB30408-23

©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.